As expected, co-occurrences of IDH2 hotspot mutations and TP53 alterations were extremely rare; there were a total of 11 cases among all three datasets, including 4 cases of lower-grade glioma, 3 cases of acute myeloid leukemia, and 2 cases of basal cell carcinoma (Figure S2). This evidence concerns the gene IDH2 and central nervous system cancer.